Attend the FiercePharmaMarketing Forum
This is a can't-miss event! Save 15% with promo code FPMF2018
Sanofi's corporate rebrand is moving online. In a website overhaul, the pharma is rolling out consumer-friendly, visual-heavy layouts.
The loan and the $192 million cash left at the end of 2017 will support a Heplisav-B sales team and the clinical trials of SD-101.
Emotion is a strong decision driver, especially in healthcare—so important, in fact, that Havas Health & You has launched a new agency to focus on it.
Apple's latest move into EHRs may be its biggest healthcare play yet—and it could help pharma companies open direct channels to consumers.
Mental health experts question whether allowing Johnson & Johnson to market its antipsychotic med Invega Sustenna as a way to prevent arrest is really a…
With an early approval for its new drug Erleada, J&J just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer.
Monday, Axovant said COO Marion McCourt would be exit “to pursue another opportunity.” Turns out, that opportunity's at Regeneron.
New research from Syneos Health finds that patients are adamant that artificial intelligence should not replace doctors.
Purdue made a splash with its plans to stop marketing opioids this week, but Endo, Teva, Allergan and J&J had already quit.
In December, Eli Lilly’s Taltz got a go-ahead to take on rival Cosentyx from Novartis in its second indication. But it’s not stopping there.